source
- AstraZeneca and Amgen’s Tezspire shows positive results in Phase 3 eosinophilic esophagitis trialAstraZeneca and Amgen continue to co‑develop and co‑commercialize Tezspire, an anti‑inflammatory therapy already approved for asthma and chronic rhinosinusitis. The partners are preparing another F…
- Scaling delivery is key for CAR T therapies to succeed in autoimmune diseasesBiopharma companies are exploring CAR T cell therapies as a potential cure for autoimmune disorders, a market that could be twice the size of oncology. While current treatments manage symptoms, the…